Cellosaurus cell line 21M18 (CVCL

Cross-references
Cell line name	21M18
Accession	CVCL_A4BK
Resource Identification Initiative	To cite this cell line use: 21M18 (RRID:CVCL_A4BK)
Comments	Group: Patented cell line. Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8670. Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized demcizumab (OMP-21M18) therapeutic antibody. Monoclonal antibody isotype: Not specified. Monoclonal antibody target: UniProtKB; Q9NR61; Human DLL4.
Species of origin	Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Category	Hybridoma
Publications	PubMed=19664991; DOI=10.1016/j.stem.2009.05.019 Timothy Hoey, Wan-Ching Yen, Fumiko Takada Axelrod, Jesspreet Basi, Lucas Donigian, Scott J. Dylla, Maureen Fitch-Bruhns, Sasha Lazetic, In-Kyung Park, Aaron Sato, Sanjeev Satyal ...Show all 15 authors... , Xin-Hao Wang, Michael F. Clarke, John Lewicki, Austin L. Gurney; Show fewer authors DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5:168-177(2009) Patent=US9376497 Austin L. Gurney, Fumiko Takada Axelrod, Timothy Hoey, Sanjeev Satyal; Compositions and methods for diagnosing and treating cancer. Patent number US9376497, 28-Jun-2016
Encyclopedic resources	Wikidata; Q105505888
Entry history
Entry creation	12-Jan-2021
Last entry update	02-May-2024
Version number	6